EXAS News

(NASDAQ:EXAS) MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatm

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET The webcast can be acces

– Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones – – Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024. “The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,” said Kevin Conroy, chairman and CEO. “In the second quarter, we delivered answers to more patients t

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current and future versions of Freenome’s blood-based, single indication, colorectal cancer (CRC) screening tests. Complete findings from the prospecti

Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and operational momentum.

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here's a look at the key details from the quarter.

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch.

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.